Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic CancerSusan Tsai, Douglas B. Evans, Ben George et al.|Annals of Surgery|2018Cited by 237
Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoodsJavier Mora, Susan Tsai, Ashley N. Krepline et al.|The American Journal of Surgery|2020Cited by 78
Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancerMohammed Aldakkak, Susan Tsai, Kathleen K. Christians et al.|HPB|2015Cited by 69
Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgeryChad A. Barnes, Kathleen K. Christians, Mariana Chávez et al.|Surgery|2019Cited by 63
Locally advanced pancreas cancer: Staging and goals of therapyN. Chatzizacharias, Kathleen K. Christians, Susan Tsai et al.|Surgery|2018Cited by 58